New offerings for the refractive surgeon

Article

The Visante omni is the first system to combine OCT and Placido disk technologies, providing comprehensive anterior and posterior topography for improved patient selection and care.

The Visante omni is the first system to combine OCT and Placido disk technologies, providing comprehensive anterior and posterior topography for improved patient selection and care. Linking two of Carl Zeiss' platforms, the Atlas corneal topographer with Visante OCT), the new Visante omni allows the refractive surgeon to identify pre-existing corneal abnormalities, such as keratoconus, in their earliest stages.

“Combining OCT pachymetry with Placido disk technology may provide the most precise information possible about the back surface of the cornea,” said Jack Holladay, MD, of Holladay Lasik Institute. In addition, the Visante omni Holladay reports, allows physicians to access patient-specific data sets in a simple, one page printout to maximize workflow and practice efficiencies.

The new 500 kHz VisuMax Femtosecond System is said by Zeiss to be more than twice the speed of the 200 kHz system. Treatment times are reduced from approximately 20 - 25 seconds to just ten seconds per eye. Laser spot density is also said to have been increased by approximately 20 per cent, facilitating more consistent flap lifts and smoother stromal beds. The new 500 kHz upgrade works with the existing VisuMax platform with no programming modifications required by the surgeon.

“Clinically, this produces two significant benefits. First, the higher repetition rate reduces the actual laser emission time, which is the critical phase of the procedure. Thus, the patient is required to remain still for a very short amount of time. Secondly, the higher spot density results in even more precise tissue separation,” said Jon Dishler, MD, of Dishler Laser Institute.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.